Tampi Rajesh R, Joshi Pallavi, Marpuri Padmapriya, Tampi Deena J
Department of Psychiatry and Behavioral Sciences, Cleveland Clinic Akron General, Akron, OH 44106, United States.
Department of Psychiatry and Behavioral Sciences, Northwell Health-Staten Island University Hospital, Staten Island, NY 10306, United States.
World J Psychiatry. 2020 Apr 19;10(4):29-33. doi: 10.5498/wjp.v10.i4.29.
Behavioral and psychological symptoms including agitation are common in dementia, and are associated with decreased quality of life, increased risk of institutionalization, and greater patient and caregiver distress. Pharmacological agents used for management of behavioral and psychological symptoms of dementia are limited by their tolerability, prompting a need for identifying efficacious and safe pharmacological treatments for managing agitation in dementia. The combination of dextromethorphan and quinidine sulfate is approved for pseudobulbar affect, and may be effective in managing agitation in dementia. A review of literature found only one randomized controlled trial that evaluated the use of dextromethorphan-quinidine for the management of agitation in dementia when compared to placebo. Data from this trial demonstrated that dextromethorphan-quinidine decreased agitation in dementia, and was well tolerated. Although promising, further research is needed before dextromethorphan-quinidine combination can be accepted as a standard treatment for agitation in dementia.
包括激越在内的行为和心理症状在痴呆症中很常见，并且与生活质量下降、入住机构的风险增加以及患者和护理人员的更大痛苦相关。用于管理痴呆症行为和心理症状的药物因其耐受性而受到限制，这促使人们需要确定有效且安全的药物治疗方法来管理痴呆症中的激越症状。右美沙芬和硫酸奎尼丁的组合被批准用于治疗假性延髓情绪，并且可能对管理痴呆症中的激越有效。一项文献综述发现，与安慰剂相比，只有一项随机对照试验评估了右美沙芬 - 奎尼丁用于管理痴呆症激越的情况。该试验的数据表明，右美沙芬 - 奎尼丁可减轻痴呆症中的激越，并且耐受性良好。尽管前景乐观，但在右美沙芬 - 奎尼丁组合被接受为痴呆症激越的标准治疗方法之前，还需要进一步研究。
